<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795428</url>
  </required_header>
  <id_info>
    <org_study_id>PB1046-PT-CL-0006</org_study_id>
    <nct_id>NCT03795428</nct_id>
  </id_info>
  <brief_title>Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004</brief_title>
  <acronym>VIP Extend</acronym>
  <official_title>A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhaseBio Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhaseBio Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the&#xD;
      safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose. This is a&#xD;
      Long-Term, Open label Extension (OLE) Study for subjects with (PAH), having participated in&#xD;
      double-blind Study PB1046-PT-CL-0004. The study will include adult subjects previously&#xD;
      diagnosed with symptomatic PAH, who are receiving background clinician-directed therapy for&#xD;
      PAH.&#xD;
&#xD;
      During this period, subjects will continue to be followed for safety and tolerability, as&#xD;
      well as for periodic efficacy, quality of life data and immunogenicity. The study will&#xD;
      continue per the schedule of events until such time when pemziviptadil (PB1046) is able to be&#xD;
      self-administered, becomes commercially available to the subjects in a particular country or&#xD;
      region, or the sponsor terminates the study due to lack of efficacy, safety or other reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects entering this study will enter from the double-blind Study PB1046-PT-CL-0004. The&#xD;
      starting dose level of pemziviptadil (PB1046) for all subjects in this parent study was a&#xD;
      sub-therapeutic or minimally effective dose (MED) of 0.2 mg/kg, administered by SC injection.&#xD;
&#xD;
      Subjects were randomized into the MED) Group or a dose-titration group. In the dose-titration&#xD;
      group, individual subjects were titrated up to their maximum tolerated dose (MTD) in a&#xD;
      blinded fashion, with the objective of titrating subjects up to a dose of at least 1.2 mg/kg&#xD;
      or higher in the MTD Group, while subjects in the MED Group remained at the MED level of 0.2&#xD;
      mg/kg, and underwent &quot;sham dose-titration&quot; to maintain the blind.&#xD;
&#xD;
      Subjects entering the 0006 trial prior to implementation of this protocol amendment will&#xD;
      remain blinded until such time that open label dosing will not unblind the 0004 study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">February 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>To protect the blind of the parent study (PB1046-PT-CL-0004), all subjects entering PB1046-PT-CL-0006 will commence dosing at Week 1 on 0.4 mg/kg and will be up-titrated in 0.2 mg/kg increments in an open label fashion for 9 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Subjects entering the 0006 trial prior to the implementation of this protocol amendment will remain blinded until such time that open label dosing will not unblind the 0004 study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinical Laboratory Abnormalities</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oral Body Temperature from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Respiratory Rate from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Rate from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Lead ECG - Incidence of clinically significant abnormal ECG findings as measured by 12 Lead ECG</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Immunogenicity</measure>
    <time_frame>Duration of extension study - Starting up to 30 days prior to first dose of study drug in original study (PB1046-PT-CL-0004/0005) and completing 28 days after last dose.</time_frame>
    <description>Incidence of positive immunogenicity results after receipt of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6MWD (6 minute walk distance test)</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>Measured in meters walked in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NT-proBNP</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NYHA/WHO Functional Class (FC)</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in emPHasis-10 (Health Related Quality of Life) score</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>Scores, which assess breathlessness, fatigue, control and confidence, range from 0 to 50, higher scores indicate worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Borg Dyspnea Index (BDI)</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>BDI scale as measured from 0 to 10 (0 being no breathlessness and 10 being maximal breathlessness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinical Worsening</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>As defined by any one of the following: 1. All cause mortality; 2. Hospitalization due to worsening PAH; 3. Initiation of parenteral prostacyclin; 4. Any three of the following: 15% decrease in 6MWD, Functional class III or IV symptoms, Addition of PAH therapy, Worsening right heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in REVEAL Registry Risk Calculator Score</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>Risk scores range from 0 (Lowest risk) to 22 (Highest risk) in PAH subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in pulmonary artery pressure from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>PB1046-PT-CL-0005 subjects only as measured by CardioMEMS device</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiac index from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>PB1046-PT-CL-0005 subjects only as measured by CardioMEMS device</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total pulmonary resistance from baseline</measure>
    <time_frame>Duration of extension study - Starting the day of first dose and completing 28 days after last dose.</time_frame>
    <description>PB1046-PT-CL-0005 subjects only as measured by CardioMEMS device</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemziviptadil (PB1046) Injection</intervention_name>
    <description>Once-weekly subcutaneous injection</description>
    <arm_group_label>Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have completed Week 17 / End of Study of PB1046-PT-CL-0004;&#xD;
&#xD;
          -  Willing and able to sign a written Informed Consent (IC) prior to all study-related&#xD;
             procedures;&#xD;
&#xD;
          -  Agrees to use a medically acceptable method of contraception (both male and female&#xD;
             patients) throughout the entire study period and continuing for 30 days after their&#xD;
             last dose of study drug. if the possibility of conception exists. Medically acceptable&#xD;
             methods of contraception include the following: abstinence (not having sex), vasectomy&#xD;
             (with confirmed negative sperm counts), condoms and partner using vaginal spermicide&#xD;
             and/or cervical cap with spermicide or sponge; oral, implantable, or injectable&#xD;
             contraceptives (starting ˃2 months before dosing), diaphragm with vaginal spermicide,&#xD;
             intrauterine device, surgical sterilization (˃6 months after surgery). Female subjects&#xD;
             ˂45 years of age of non-childbearing potential are defined as being surgically sterile&#xD;
             by bilateral tubal ligation, bilateral oophorectomy, or hysterectomy. Female subjects&#xD;
             45to-60 years of age, inclusive, who are post-menopausal for at least 1 year, and have&#xD;
             a follicle-stimulating hormone (FSH) level confirmation indicating post-menopausal&#xD;
             status, will be considered to be of non-childbearing potential. Female subjects &gt; 60&#xD;
             years of age are considered post-menopausal and of non-childbearing potential;&#xD;
&#xD;
          -  Willing and able to understand and follow instructions, return to the study unit for&#xD;
             specified study visits; and, be able to participate in the study through the Stable&#xD;
             Dose Maintenance Period, at a minimum.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant medical disorder, condition, or history, that in the opinion of the&#xD;
             Investigator, would impair the subject's ability to participate in or complete the&#xD;
             requirements of the study;&#xD;
&#xD;
          -  Pregnant or lactating female subjects;&#xD;
&#xD;
          -  Significant liver dysfunction as measured by any one of the following during&#xD;
             participation in PB1046-PT-CL-0004. (If exclusionary laboratory results become&#xD;
             available after the subject has enrolled in PB1046-PT-CL-0006 they should be&#xD;
             discontinued. a. alanine aminotransferase (ALT) &gt; 3.0 times upper limit of normal&#xD;
             (ULN) or; b. aspartate aminotransferase (AST) &gt; 3.0 times ULN or; c. serum bilirubin ≥&#xD;
             1.6 mg/dL.&#xD;
&#xD;
          -  Recent history of substance abuse that, in the opinion of the Investigator, would&#xD;
             impair the subject's ability to participate in or complete the requirements of the&#xD;
             study;&#xD;
&#xD;
          -  In the opinion of the principal investigator (PI), any major surgical procedure within&#xD;
             90 days, or a planned surgical procedure during the study period; which would impact&#xD;
             participation in PB1046-PT-CL-0006.&#xD;
&#xD;
          -  Other new medical or psychiatric conditions which, in the opinion of the Investigator,&#xD;
             would place the subject at increased risk, would preclude obtaining voluntary consent,&#xD;
             or would confound the objectives of the study;&#xD;
&#xD;
          -  Known hypersensitivity to study drug or any of the excipients of the drug formulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola M Ceren</last_name>
      <phone>858-657-7135</phone>
      <email>pmm001@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>David S Poch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Jaha</last_name>
      <phone>916-734-1554</phone>
      <email>nkjaha@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Roblee Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Pulmonary Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David De La Zerda, MD</last_name>
      <phone>305-243-9383</phone>
      <email>enf16@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emilia Faraj</last_name>
      <phone>305-243-9383</phone>
      <email>enf16@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David De La Zerda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University, The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Gillespie</last_name>
      <phone>404-712-8204</phone>
      <email>jane.gillespie@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Micah Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Parks, RN, BSN</last_name>
      <phone>319-353-5236</phone>
      <email>traci-parks@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Linda M Cadaret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Boccardi</last_name>
      <phone>913-588-4022</phone>
      <email>lboccardi@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie A Spikes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abigail Pires</last_name>
      <phone>617-636-3269</phone>
      <email>apires@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Ioana Preston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Vayer</last_name>
      <phone>617-525-9731</phone>
      <email>Ovayer@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diana Acuna</last_name>
      <phone>617-732-4954</phone>
      <email>Dacuna@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Waxman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabela Barroso</last_name>
      <phone>212-263-9189</phone>
      <email>anabela.barroso@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Roxana Sulica, MD</last_name>
      <phone>212-263-9189</phone>
      <email>roxana.sulica@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Roxana Sulica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Mintz, RN</last_name>
      <phone>585-486-0869</phone>
      <email>urmc_pahresearch@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>R. James White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Anderson</last_name>
      <phone>513-585-1777</phone>
      <email>ellen.anderson@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Peter Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Elwing, MD</last_name>
      <phone>513-558-4831</phone>
      <email>jean.elwing@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INTEGRIS Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Roach</last_name>
      <phone>405-552-0419</phone>
      <email>amanda.roach@integrisok.com</email>
    </contact>
    <investigator>
      <last_name>John F Kingrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amresh Raina, MD</last_name>
      <phone>412-737-4760</phone>
      <email>Amresh.Raina@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Amresh Raina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Shoemaker</last_name>
      <phone>412-692-2769</phone>
      <email>shoeka@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Simon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Bartolome, MD</last_name>
      <phone>214-645-6493</phone>
      <email>sonja.bartolome@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Sonja Bartolome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>VIP-ELP fusion molecule PB1046</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

